Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

J Lorscheider; VG Jokubaitis; T Spelman; G Izquierdo; A Lugaresi; E Havrdova; D Horakova; M Trojano; P Duquette; M Girard; A Prat; F Grand'Maison; P Grammond; E Pucci; C Boz; P Sola; D Ferraro; D Spitaleri; J Lechner-Scott; M Terzi; V Van Pesch; G Iuliano; R Bergamaschi; C Ramo-Tello; F Granella; C Oreja-Guevara; H Butzkueven; T Kalincik

Journal article

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

J Lorscheider, VG Jokubaitis, T Spelman, G Izquierdo, A Lugaresi, E Havrdova, D Horakova, M Trojano, P Duquette, M Girard, A Prat, F Grand'Maison, P Grammond, E Pucci, C Boz, P Sola, D Ferraro, D Spitaleri, J Lechner-Scott, M Terzi Show all

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017

DOI: 10.1212/WNL.0000000000004330

Abstract

To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an international cohort study, we previously validated a highly accurate definition of SPMS. Here, we identified patients in MSBase who were either untreated or treated with a disease-modifying drug when meeting this definition. Propensity score matching was used to select subpopulations with comparable baseline characteristics. Disability outcomes were compared in paired, pairwise-censored analyses adjusted for treatment persistence, visit density, and relapse rates. Results: Of the 2,381 included patients, 1,378 patients were ..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Tomas Kalincik Author

Neil Shuey Author

Related Projects (4)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by Biogen

Funding Acknowledgements

This study was financially supported by Biogen (Fellowship in MS Registries Research), the National Health and Medical Research Council (practitioner fellowship 1,080,518; project grants 1,083,539 and 1,129,189; and Centre for Research Excellence 1,001,216), and the University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship). The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Bayer, Genzyme, Teva, and Sanofi-Aventis. The study was conducted separately and apart from the guidance of the sponsors.